Skip to main content
Guizhou Yibai Pharmaceutical Co.,Ltd logo

Guizhou Yibai Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 600594 ISIN · CNE000001H03 LEI · 300300PEY30XPH5CB779 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600594

About Guizhou Yibai Pharmaceutical Co.,Ltd

https://www.gzcci.com/

Guizhou Yibai Pharmaceutical Co.,Ltd. specializes in the research, development, production, and distribution of modern Chinese medicines and chemical pharmaceuticals. The company focuses on therapeutic areas such as oncology, cardiovascular diseases, and respiratory conditions. Its product portfolio includes specialized treatments like Aidi Injection, which is widely utilized in clinical oncology. By integrating traditional herbal knowledge with modern pharmaceutical technology, the company maintains a strong presence in the healthcare market. Its operations encompass the entire value chain, from the cultivation of medicinal herbs to the manufacturing of finished dosage forms, ensuring quality control and therapeutic efficacy across its diverse range of prescription and over-the-counter products.

Recent filings

Filing Released Lang Actions
贵州益佰制药股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the 2025 Annual General Meeting resolutions, detailing attendance, each proposal voted on, and the voting results. It is not the meeting materials or the full annual report; rather it is the formal declaration of voting outcomes at a shareholders’ meeting. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2026-05-20 Chinese
贵州益佰制药股份有限公司关于变更回购股份用途并注销暨通知债权人的公告
Transaction in Own Shares Classification · 90% confidence The document is an official announcement by the board of 贵州益佰制药股份有限公司 concerning the change of purpose of previously repurchased shares and their cancellation with a corresponding reduction in registered capital, including creditor notification procedures. This falls under disposal of own shares (repurchased shares) and capital reduction, which is classified as a Transaction in Own Shares.
2026-05-20 Chinese
贵州益佰制药股份有限公司独立董事2025年年度述职报告（陈怡松离任）
Board/Management Information Classification · 95% confidence The document is an Independent Director's Annual Work Report for the year 2025 for Guizhou Yibai Pharmaceutical Co., Ltd. It details the director's background, attendance at board and committee meetings, communication with auditors, protection of investor rights, and evaluation of company governance and compliance during the reporting period. The content is focused on the director's duties and activities rather than financial statements or audit results. It is not a full Annual Report (10-K), Audit Report (AR), or Interim Report (IR). It is also not a simple announcement or certification but a detailed report on the director's management and governance role. This fits best under Board/Management Information (MANG), which covers announcements and reports related to changes or activities of the company's board or senior management, including independent directors' reports.
2026-04-22 Chinese
贵州益佰制药股份有限公司关于计提2025年年度相关资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Guizhou Yibai Pharmaceutical Co., Ltd. regarding the provision for asset impairment for the fiscal year 2025. It details the amounts of impairment losses on goodwill, inventory, fixed assets, and credit losses, referencing specific accounting standards and the board's approval. The document is relatively short (1978 characters) and serves as a formal disclosure of the impairment provision rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or a simple notice of report publication. The content fits best with a Regulatory Filing (RNS) as it is a regulatory disclosure about asset impairment provisions without being a full audit or annual report.
2026-04-22 Chinese
贵州益佰制药股份有限公司2025年年度报告
Annual Report Classification · 100% confidence The document is titled "贵州益佰制药股份有限公司2025 年年度报告" which translates to "Guizhou Yibai Pharmaceutical Co., Ltd. 2025 Annual Report." It contains detailed financial data, management discussion and analysis, company overview, financial indicators, audit report mention, and comprehensive business and industry analysis. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of audited financial statements, management discussion, and detailed financial metrics confirms this is the official yearly report covering company activity and full financial performance for the fiscal year 2025. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-22 Chinese
贵州益佰制药股份有限公司2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '贵州益佰制药股份有限公司2026年第一季度报告' which translates to 'Guizhou Yibai Pharmaceutical Co., Ltd. 2026 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes for the first quarter of 2026. The report explicitly states it is unaudited and covers the quarterly period (January to March 2026). The length of the document (13,265 characters) and the presence of comprehensive financial statements and analysis confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.